IGF-1 LR3: Why the Exact Molecule Matters
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

IGF-1 LR3, also called Long Arg3 IGF-I, is an engineered analogue. Its sequence differs from natural IGF-1, so the exact molecule matters. An early study compared these analogues in cell models and examined interactions with IGF-binding proteins. Those experiments help explain laboratory activity, not clinical muscle gains. Mecasermin is a different prescription product with FDA-approved uses for specific pediatric growth disorders. Its approval does not establish an approval or benefit for LR3. Changing a growth-factor molecule can change its behavior. Evidence must match the exact compound, outcome and population before laboratory potency becomes a clinical claim.

END CARD
Educational draft. Not medical advice. Sources and limitations accompany this film.

SOURCES
[1] Francis et al. (1992): Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency
https://pubmed.ncbi.nlm.nih.gov/1378742/
Primary engineered-analogue and cell study; abstract reviewed

[2] FDA: INCRELEX (mecasermin) prescribing information, revised July 2025
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021839s033lbl.pdf
US prescribing information for a distinct drug

EVIDENCE LIMITATIONS
Do not transfer the mecasermin indication, dose, efficacy or safety profile to LR3.
Greater potency in a cell assay does not establish superior clinical benefit or safety.
The script does not imply that all IGF-1 formulations are interchangeable.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Original topic requested by Nina; not attributed to an additional verified Facebook video.